This Isn ’t Walmart: The Supreme Court Narrows Forum-Shopping Options

This article outlines the background, the case decision, and the decision’s ramifications to companies.

As the arguments about why pharmaceutical prices are rising so quickly grow more contentious, so too has the debate about tort reform and products liability. Recently, during one of last days of its most recent term, the United States Supreme Court (“SCOTUS”) issued a decision that will make it harder for plaintiffs to sue corporations in state courts for damages caused by manufacturers’ products. The nearly unanimous decision in Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco County, et al., has been hailed as “one of the most important mass tort/product liability decisions.”
To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In

      Related StoriesThe Fine Art of Policy ManagementIndependent Review Organizations (“IRO”) and Conflicts of Interest - Much Ado About Nothing or a Serious ProblemA New Application of Escobar: Gilead or When Half-Truths Can Become Actionable Under the FCA 

Source: Policy and Medicine - September 6, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs